


Psychopharmacology Update 30

For psychiatrists and all physicians
interested in psychopharmacology

Saturday, January 26, 2019

The Olympic Collection
11301 W. Olympic Blvd.
Los Angeles, CA 90064



Psychopharmacology Update 30

Saturday, January 26, 2019

Southern California Psychiatric Society
2999 Overland Avenue, Suite 208
Los Angeles, CA 90064

Southern California Psychiatric Society
**Psychopharmacology
Update 30**
Saturday, January 26, 2019
The Olympic Collection

Please Print

Name: _____

Address: _____

City/State/Zip: _____

Email: _____

Attending

SCPS Member	\$200	_____
Non-SCPS Member	\$225	_____
SCPS Resident *	\$30	_____
Non-SCPS Resident *	\$40	_____

Total enclosed: \$ _____

Above fees effective until 1/15/19. All registrations after 1/15/19 and at-door registrations are an additional \$25.

**Must be enrolled in a full-time, degree granting program. Must send photocopy of student I.D. with registration form. NO EXCEPTIONS.*

Please make check payable to SCPS and mail w/ this registration form to: SCPS, 2999 Overland Av., #208, Los Angeles, CA 90064.

**You may also pay online at our Website via Paypal
Go to: socialpsych.org/event-registration.html
to register online.**

Cancellations must be received 48 hours prior to the meeting and will be assessed a \$45 administrative processing fee.

Psychopharmacology Update 30

8:15 a.m. - Registration, Continental Breakfast, Booth Exhibits

8:55 a.m. - Opening Remarks

9:00 a.m. - Treatment of Obesity with Emphasis on Topics of Interest to Psychiatrists

Frank Greenway, M.D., Medical Director and Professor, Pennington Biomedical Research Center Baton Rouge, Louisiana

This talk will discuss the role played by the reward system compared to the hypothalamic hunger system by drugs approved for the treatment of obesity. We will discuss the cannabinoid system and potential approaches to treating obesity and avoiding the depression problems seen with cannabinoid-1 inverse agonists like rimonabant. Causing weight loss at the body locations people feel are problem areas as a way of improving self-image when losing weight will also be discussed.

10:15 a.m. - Break

10:30 a.m. - Neuromodulation: The Future of Treatment for Neuropsychiatric Illness

Andrew Leuchter, M.D., Professor of Psychiatry and Biobehavioral Sciences; Director, TMS Clinical and Research Service; Director, Neuromodulation Division.

Neuromodulation treatments are an emerging class of technologies that apply magnetic or electrical energy to the brain to treat depression, Obsessive-Compulsive Disorder, chronic pain, and other neuropsychiatric illnesses. Neuromodulation treatments can be used as either an alternative or an addition to medications for the treatment of illness. These cutting edge technologies modify the activity of neural networks, and include non-invasive methods that utilize electromagnets or small electrodes applied to the scalp, and invasive techniques that involve insertion of electrodes into the brain. Non-invasive treatments include repetitive Transcranial Magnetic Stimulation (rTMS), Electroconvulsive Therapy (ECT), transcranial Direct Current Stimulation (tDCS), Trigeminal Nerve Stimulation (TNS), and synchronized Transcranial Magnetic Stimulation (sTMS). Invasive techniques include Deep Brain Stimulation (DBS) and Vagal Nerve Stimulation (VNS). These techniques offer new hope for the the treatment of patients who have received inadequate benefit from medications. This talk will review the effectiveness of neuromodulation treatments that currently are available, as well as major experimen-

tal treatments in development.

11:45 a.m. - Lunch Break (lunch on our own)

1:00 p.m. - An Update on Anxiety Disorders

Mark H. Pollack, M.D., The Grainger Professor and Chairman, Department of Psychiatry, Rush University Medical Center

This talk will review pharmacologic strategies to improve the outcomes for treatment of individuals with anxiety disorders.

2:15 p.m. - The Top Ten Drug Interactions that Limit Efficacy in Psychiatric Treatment

Paul Zarkowski, M.D., Clinical Assistant Professor, Department of Psychiatry and Behavioral Sciences, Harborview Medical Center, University of Washington; Psychiatrist, Seattle, Washington.

Although there are numerous resources to guide prescribers away from harmful drug interactions and pharmacokinetic interactions, there is less written on interactions that limit efficacy. These are common and can be grouped in three categories: functional drug interactions with opposing functions and side effect profiles, drug interactions with antagonistic mechanisms of action and controversial drug interactions with opposing pharmacology. Each of these categories is represented in the top ten drug interactions that limit efficacy. The relative prevalence of each efficacy limiting interaction will be presented and discussed.

Please Call (310) 815-3650 for any Questions or Concerns.

SCPS would like to thank: *Michael Gales, M.D. (Program Chair), David Fogelson, M.D., Jacquelyn Green, M.D., Samuel Miles, M.D., and Heather Silverman, M.D.* for planning this event

Overview

This program begins with evidence-based treatments for obesity deploying pharmacologic, behavioral, and surgical approaches. Health disparities associated with obesity and the relevance of anti-obesity bias to effective treatment will also be addressed. Our second presentation covers the emerging class of technologies grouped as neuromodulation techniques and the specific conditions they treat. Both invasive and non-invasive treatments will be considered, encompassing experimental treatments in development.

After lunch, we will hear a review of state-of-the-art pharmacologic strategies to improve the outcomes for treatment of individuals with anxiety disorders. Our last presentation of the day will examine the 10 top drug interactions that limit efficacy in psychiatric treatment. While harmful drug interactions and pharmacokinetic interactions are frequently addressed, there is much less attention to interactions that limit medication efficacy.

Objectives

At the end of this seminar, participants will have:

- 1) An enhanced knowledge of evidence-based treatments for obesity including strategies for managing implicit and explicit forms of anti-obesity bias.
- 2) Applicable knowledge of the emerging class of neuromodulation treatments for a broad range of neuropsychiatric illnesses and the mechanisms of action.
- 3) Understanding of the current recommended strategies to improve the outcomes of the treatment of anxiety disorders.
- 4) Knowledge of the top 10 drug interactions that limit efficacy in psychiatric treatment and how to manage them.

Continuing Education

The Southern California Psychiatric Society is accredited by the Institute for Medical Quality/California Medical Association (IMQ/CMA) to provide continuing medical education for physicians. The Southern California Psychiatric Society takes responsibility for the content, quality and scientific integrity of this CME activity.

The Southern California Psychiatric Society designates this educational activity for a maximum of 5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.

